Clinical Trials Logo

Myocardial Ischemia clinical trials

View clinical trials related to Myocardial Ischemia.

Filter by:

NCT ID: NCT05292118 Recruiting - Clinical trials for Ischemic Heart Disease

Navitian PMCF Study ( rEPIC04C )

rEPIC04C
Start date: September 26, 2022
Phase:
Study type: Observational

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Navitian to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Navitian.

NCT ID: NCT05292105 Completed - Clinical trials for Ischemic Heart Disease

NC Xperience PMCF Study( rEPIC04B)

rEPIC04B
Start date: September 26, 2022
Phase:
Study type: Observational

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of NC Xperience to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with NC Xperience .

NCT ID: NCT05292092 Recruiting - Clinical trials for Ischemic Heart Disease

Essential Pro PMCF Study ( rEPIC04E )

rEPIC04E
Start date: September 26, 2022
Phase:
Study type: Observational

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Essential Pro to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Essential Pro.

NCT ID: NCT05292079 Recruiting - Clinical trials for Ischemic Heart Disease

CAPTURER PMCF Study ( rEPIC04D )

rEPIC04D
Start date: September 29, 2022
Phase:
Study type: Observational

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of CAPTURER to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with CAPTURER .

NCT ID: NCT05292014 Recruiting - Clinical trials for Ischemic Heart Disease

ANGIOLITE PMCF Study ( rEPIC04F )

rEPIC04F
Start date: September 26, 2022
Phase:
Study type: Observational

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Angiolite sirolimus eluting stent to meet EU Medical Device regulation (MDR) requirements in all the CONSECUTIVE patients treated with Angiolite sirolimus eluting stent.

NCT ID: NCT05288361 Recruiting - Clinical trials for Endothelial Dysfunction

The DISCOVER INOCA Prospective Multi-center Registry

DISCOVER INOCA
Start date: September 14, 2022
Phase:
Study type: Observational [Patient Registry]

The overall objective of this multi-center registry is to identify specific phenotypes of INOCA with both an anatomic evaluation (coronary angiography and intravascular imaging) and physiologic assessment with the Abbott Coroventis Coroflow Cardiovascular System, and to determine long-term outcomes.

NCT ID: NCT05279651 Recruiting - Myocardial Ischemia Clinical Trials

Ivabradine for Prevention of Myocardial Injury After Noncardiac Surgery Trial (PREVENT-MINS)

PREVENT-MINS
Start date: June 13, 2022
Phase: Phase 3
Study type: Interventional

This study is a multicentre, randomized controlled trial of ivabradine versus placebo.

NCT ID: NCT05278819 Completed - Heart Diseases Clinical Trials

Upper Extremity Elevation and Lungfunction After Open Heart Surgery

Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to assess if arm elevation, with or without simultaneous deep breathing, affects oxygen saturation and lung function on patients two to four days after open heart surgery.

NCT ID: NCT05271591 Completed - Clinical trials for Cardiovascular Diseases

Generalizability of REDUCE-IT Results to People of South Asian Descent With Atherosclerotic Cardiovascular Disease in Canada (REDUCE-IT Canada SA)

Start date: March 5, 2022
Phase:
Study type: Observational

The REDUCE-IT Canada SA Study is a cross-sectional study aiming to determine the proportion of study participants who meet the Health Canada-approved indication for icosapent ethyl (IPE;Vascepa®).

NCT ID: NCT05271448 Recruiting - Clinical trials for Chronic Kidney Diseases

Continuing or Discontinuing ACE/ARBs in Patients With Chronic Kidney Disease Undergoing Coronary Angiography

Start date: June 1, 2021
Phase: N/A
Study type: Interventional

Contrast induced nephropathy (CIN) is a well-known possible complication of percutaneous coronary intervention (PCI) with an incidence varies from 3.3% to 14.5% in patients undergoing PCI. Many previous randomized and non-randomized studies have shown very conflicting results regarding the use of ACE-Is prior to coronary angiography, and whether it decreases or increases the risk of CIN. The importance of this study is to help find an acceptable and reliable answer for the use of ACE-I/ARBs prior to cardiac catheterization. This research aims to study the effect of withholding ACE-Is or ARBs on the incidence of contrast induced nephropathy in patients undergoing coronary angiography who have chronic kidney disease (GFR<60 ml/min/1.73 m2) and to help build evidence-based data and guidelines on the safety of continuing or withholding ACE-I/ARBs pre contrast administration.